Wage Justin, Mignano John, Wu Julian
Department of Radiation Oncology, Tufts Medical Center, Boston, Massachusetts.
Department of Radiation Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
Adv Radiat Oncol. 2021 Apr 28;6(4):100687. doi: 10.1016/j.adro.2021.100687. eCollection 2021 Jul-Aug.
Our purpose was to evaluate the long-term outcomes of patients with vestibular schwannoma (VS) treated with Gamma Knife stereotactic radiosurgery (GKSRS) with modern techniques, with attention to posttreatment tumor growth dynamics, dosimetric predictors, and late toxicities.
One hundred twelve patients with VS were treated with GKSRS with a median dose of 12.5 Gy to the 50% isodose line treated between 2004 and 2015, with patients followed up to 15 years. Target and organ-at-risk doses were recorded, and tumor diameter/volume, audiologic decline, and trigeminal/facial nerve preservation were tracked from treatment onward.
GKSRS yielded local control of 5, 10, and 15 years at 96.9%, 90.0%, and 87.1% respectively. Pseudoprogression was found in 45%, with a novel pattern detected with peak swelling at 31 months. Pseudoprogression was associated with smaller tumor diameter at treatment and fewer treatment isocenters, but not with the development of any toxicity, nor was it predicted by any dosimetric factor. Median time to hearing loss was 3.4 years with actuarial hearing preservation at 2, 5, and 10 years of 66.5%, 43.1%, and 37.6%, with rate of hearing loss correlating with maximum cochlea and modiolus doses. Trigeminal and facial nerve preservation rates were 92.7% and 97.6%, respectively. Increasing maximum tumor dose was associated with facial paresthesia.
Modern GKSRS is a safe and effective treatment for VS on long-term follow-up, with high levels of facial and trigeminal nerve preservation. A novel pattern of pseudoprogression has been identified suggesting longer imaging follow-up may be needed before initiating salvage in those without symptomatic progression. Several tumor and dosimetric predictors have been suggested for the development of different toxicities, requiring further evaluation.
我们的目的是评估采用现代技术的伽玛刀立体定向放射外科治疗(GKSRS)前庭神经鞘瘤(VS)患者的长期疗效,关注治疗后肿瘤生长动态、剂量学预测指标和晚期毒性。
112例VS患者接受了GKSRS治疗,2004年至2015年间50%等剂量线的中位剂量为12.5 Gy,患者随访长达15年。记录靶区和危及器官的剂量,并从治疗开始跟踪肿瘤直径/体积、听力下降情况以及三叉神经/面神经保留情况。
GKSRS在5年、10年和15年时的局部控制率分别为96.9%、90.0%和87.1%。45%的患者出现假性进展,发现一种新的模式,在31个月时肿胀达到峰值。假性进展与治疗时较小的肿瘤直径和较少的治疗等中心有关,但与任何毒性的发生无关,也没有任何剂量学因素能够预测。听力丧失的中位时间为3.4年,2年、5年和10年时的精算听力保留率分别为66.5%、43.1%和37.6%,听力丧失率与耳蜗和蜗轴的最大剂量相关。三叉神经和面神经保留率分别为92.7%和97.6%。最大肿瘤剂量增加与面部感觉异常有关。
现代GKSRS对VS进行长期随访是一种安全有效的治疗方法,对面神经和三叉神经保留水平较高。已识别出一种新的假性进展模式,提示在无症状进展的患者中开始挽救治疗前可能需要更长时间的影像学随访。已提出了几种肿瘤和剂量学预测指标用于不同毒性的发生,需要进一步评估。